ANTX vs EXC · $32.0M cap vs P/E 17, rev $24.26B
AN2 Therapeutics Inc (ANTX) versus Exelon Corporation (EXC) — a side-by-side from cached financials, not a winner call.
AN2 Therapeutics Inc (ANTX) is a biotechnology company listed on US.
Exelon Corporation (EXC) is a utilities - regulated electric company listed on NASDAQ.
ANTX does not have a complete income-statement cache yet.
Latest reported EXC revenue for 2025-12-31 was $24.26B. Net income was $2.77B. Revenue was up 5.3% from 2024-12-31 to 2025-12-31. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
ANTX currently screens at market cap $32.0M. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
Not investment advice. Open the ANTX and EXC stock pages for the full models.
Not investment advice.